Associated Papers
Landscape of Clinically Relevant Genomic Alterations in the Indian Non-small Cell Lung Cancer Patients.
Jha P et al.
Clinical Lung Cancer, 2024
Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S et al.
Cancer Medicine, 2024
38572952 (PubMed )
Supplement: CAM4-13-e7162-s003.xlsx › DNA_mutations
Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y et al.
Scientific Reports, 2024
38238401 (PubMed )
Supplement: 41598_2024_52006_MOESM5_ESM.xlsx › combie_list
Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures.
Guerin N et al.
Cell Systems, 2022
Prognostic value of baseline genetic features and newly identified TP53 mutations in advanced breast cancer.
Zhang L et al.
Molecular Oncology, 2022
35971249 (PubMed )
Supplement: MOL2-16-3689-s005.xlsx › Table_S3
A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Koopman B et al.
Cancers, 2021
Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
Zhou Z et al.
Cancer Biology & Medicine, 2021
EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes.
Jin R et al.
Frontiers in Oncology, 2021
34195081 (PubMed )
Supplement: Table_2.xlsx › EGFR-Mutant_ADC
EGFR G796D mutation mediates resistance to osimertinib.
Zheng D et al.
Oncotarget, 2017
Select a paper to view details